Aclaris Therapeutics Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Valuation Ratios
P/S Ratio14.182.3835.30131.6742.84
P/B Ratio1.710.475.324.517.38
Price/Tangible Book1.710.475.514.689.10
Enterprise Value Ratios
EV/Revenue5.0627.0496.0936.79
Profitability & Returns
Return on Equity (ROE)-0.84%-0.50%-0.44%-0.77%-0.95%
Return on Assets (ROA)-0.16%-0.32%-0.21%-0.25%-0.36%
Return on Capital Employed (ROCE)-0.28%-0.69%-0.37%-0.29%-0.87%
Leverage & Solvency Ratios
Debt/Equity0.020.020.010.010.38
Liquidity Ratios
Current Ratio3.994.1610.558.943.87
Quick Ratio3.883.869.948.383.69
Efficiency Ratios
Asset Turnover0.090.140.120.040.08
Yield & Distribution Ratios
Earnings Yield-0.50%-1.19%-0.08%-0.10%-0.18%
FCF Yield-0.08%-1.07%-0.06%-0.06%-0.14%
Buyback Yield-0.11%-0.07%-0.15%-0.33%-0.03%